Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
| ▸ | POLRMT | O00411 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22434991 | 1.00 | CSNK2A2 (0.31) | CSNK2A2CSNK2A1POLRMTDRD2RIPK1 | |
| SCHEMBL19344275 | 0.94 | CSNK2A2 (0.33) | CSNK2A2CSNK2A1POLRMTRIPK1DOT1L | |
| SCHEMBL22435101 | 0.94 | CSNK2A2 (0.33) | CSNK2A2CSNK2A1POLRMTRIPK1DOT1L | |
| SCHEMBL19344504 | 0.91 | DRD2 (0.30) | DRD2 | |
| SCHEMBL19344280 | 0.89 | CSNK2A2 (0.30) | CSNK2A2CSNK2A1POLRMT | |
| SCHEMBL19344507 | 0.85 | BRD4 (0.31) | — | |
| SCHEMBL19343949 | 0.83 | CSNK2A2 (0.32) | CSNK2A2CSNK2A1DOT1L | |
| SCHEMBL23584758 | 0.83 | DOT1L (0.33) | CSNK2A2CSNK2A1DRD2RIPK1DOT1L | |
| SCHEMBL19343942 | 0.83 | POLRMT (0.32) | POLRMT | |
| SCHEMBL19343946 | 0.83 | DOT1L (0.31) | POLRMTDOT1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200289539-A1 | NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-17 | — | — | US | disclosed |
| WO-2017153186-A1 | SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289539-A1 | NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | CSNK2A2 1659/4885CSNK2A1 1538/4885POLRMT 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.